Novo Nordisk A/S - share repurchase programme

What happened

Novo Nordisk is buying back its own B shares under a programme of up to DKK 15 billion running for 12 months from 4 February 2026. The current phase, started 6 May 2026, allows purchases of up to DKK 11,200,000,010.45 until 1 February 2027.

Confirmed

Global impact / market context

A buyback uses company cash to purchase its own shares, reducing the number of shares outstanding. That can support the share price and lift profit per share, which means earnings divided by fewer shares, but it also uses cash that could fund research, dividends or debt reduction.

Analyst inference

The company already holds 54,314,876 B shares as treasury shares, equal to 1.2% of its share capital in the article. Investors often read steady buyback execution as a signal of confidence in cash generation, though the size relative to total shares appears modest.

Analyst inference

What to watch

1. Track the daily transaction disclosures, which list the number of B shares bought, the average purchase price and the transaction value in Danish kroner. These show how quickly the DKK 11,200,000,010.45 limit is being used. Confirmed
2. Watch whether Novo Nordisk stays within the Safe Harbour Rules, which are legal protections for buybacks that follow fixed disclosure and trading conditions. Any departure could raise regulatory questions. Proposed
3. Monitor whether buybacks continue at a steady pace through 1 February 2027, since a slowdown could suggest the company is preserving cash for other priorities such as research spending or dividends. Analyst inference

Evidence

• globenewswire.com